Method and apparatuses for forming gel droplets including biological tissue (e.g., cells), and in particular, methods and apparatuses for removing oil from the gel droplets comprising dissociated cells (including micro-organospheres) are described herein. Although it is beneficial to use oil in the formation of these gel droplets, and particularly micro-organospheres, oil may inhibit growth and survival of the cells within the gel droplets. The methods and apparatuses described herein may permit the removal of oil and may enhance survival and quality of the resulting gel droplets.

A microfluidic chip for culturing and real-time monitoring of multicellular tissues and use method thereof. The chip comprises a glass substrate layer, and a PDMS microchannel layer located on the glass substrate layer, wherein the glass substrate layer comprises a glass substrate, and a plurality of microelectrodes thereon; the PDMS microchannel comprises a plurality of independent microfluidic channels; the microelectrodes on the glass substrate are in one-to-one correspondence with the microfluidic channels in the PDMS microchannel layer; and the microelectrodes are electrically connected to an external circuit. The use method comprises: cell capture, cell or tissue culture, electrical impedance spectroscopy detection, and tissue release.

A device for simulating a function of a tissue includes a first structure, a second structure, and a membrane. The first structure defines a first chamber. The first chamber includes a matrix disposed therein and an opened region. The second structure defines a second chamber. The membrane is located at an interface region between the first chamber and the second chamber. The membrane includes a first side facing toward the first chamber and a second side facing toward the second chamber. The membrane separates the first chamber from the second chamber.

Provided herein relates to devices for simulating a function of a tissue and methods of using the same. In some embodiments, the devices can be used to simulate a function of a human liver tissue. In some embodiments, the devices can be used to simulate a function of a dog liver tissue. Endothelial cell culture media for long-term culture of endothelial cells are also described herein.

The present invention is directed towards a microfluidic device comprising a first compartment comprising an inlet that is connectable to a fluidic control unit and a second compartment, wherein the first and second compartments are connected by a micrometer channel so as to allow fluid communication between the two compartments. The device also comprises an air-lock element in fluid communication with the second compartment and the air-lock element is configured so that in use the internal atmosphere of the device is sealed from the external atmosphere and so that when fluid is introduced or withdrawn from the first compartment via the inlet the air-lock element maintains an overall constant pressure within the device.

The present invention is also directed towards a method of manufacturing the microfluidic device, a kit-of-parts comprising the microfluidic device and a method of using the microfluidic device for accommodating, growing, culturing, isolating, treating and/or processing cells.

A 3D scaffold (3-dimensional scaffold) is comprised of a biocompatible polymer. The 3D scaffold includes a recess that is open towards the top side of the 3D scaffold as a colonization chamber for biological cells, a canal-type vessel, which at least partially surrounds the colonization chamber, a filling opening for the canal-type vessel, and an outlet opening for the canal-type vessel. A production method for the 3D scaffold is also provided and the 3D scaffold is used for colonizing the colonization chamber with biological cells.

This invention consists of a method for the development of personalized target anticancer therapies based on aptamers and through the systemic modeling of an individual in microfluidic devices. This invention is embodied in microfluidic devices, connections, systems, and methods for the development specific aptamers for the relevant complex biological environment targets. In a first mode, the invention provides methods for the development of target therapies which involves the maintenance of target cancerous cells in co-culture with non-target and non-cancerous cells by using microfluidic devices modularly arranged in closed systems for the development of aptamers. In a second mode, the invention provides a method for the development of target therapies, which includes the maintenance of target cells in co-culture with non-target cells by using microfluidic devices modularly arranged in closed systems. In this case, the invention provides the development of aptamers for the relevant target in homeostatic balance with the components of the fluid conditioned by the co-culture with non-target cells.

Described herein is a human, cardiovascular platform for assessing cardiotoxicity of novel/existing chemotherapeutic agents that takes advantage of microfluidic organ chip systems to examine interaction between hiPSC-derived cardiovascular cells in an integrated system. Human induced pluripotent stem cell derived cardiomyocytes (hiPSC-CMs) and human induced pluripotent stem cell derived endothelial cells (hiPSC-ECs) can serve as an in-vitro platform for assessing disease pathology, including infectious disease, evaluate drug efficacy, toxicity, cardiotoxicity and cardioprotection. This includes evaluating VEGFR2/PDGFR-inhibiting tyrosine kinase inhibitors and drug efficacy in a viral infection model, including coronaviruses. They are scalable, functionally-active cell types that mimic the cells comprising the myocardium and systemic vasculature.

A system, apparatus, and method include a pump to deliver vapor including airborne contaminants including organic compounds including a target analyte; a collector to transfer the airborne contaminants by autonomous liquid extraction into a mobile organic liquid phase; a micro-fluidic chamber including immobilized biorecognition elements that bind to analytes delivered from the mobile organic liquid phase; a mechanism to introduce the mobile organic liquid phase to a buffer containing a plurality of substrates causing a series of biochemical reactions that create a change corresponding to a concentration of the target analyte; and a detector to perform real-time analysis that correlates to a concentration of the organic compounds to determine a presence of the target analyte.

The present invention provides compositions, systems, kits, and methods for combining a. single myeloma cell and a single B-cell (e.g., from an animal exposed to a desired antigen) via discrete entity (e.g., droplet) microfluidics. In certain embodiments, a microfluidic device is used to merge a discrete entity containing a B-cell, and a discrete entity containing a myeloma cell, and a discrete entity containing gellable material, at a merger region via a trapping element in order to generate a combined discrete entity. In further embodiments, the combined discrete entity is treated such that a gelled discrete entity is formed.